Literature DB >> 7474139

An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.

J Konvalinka1, M A Litterst, R Welker, H Kottler, F Rippmann, A M Heuser, H G Kräusslich.   

Abstract

Infectious retrovirus particles are derived from structural polyproteins which are cleaved by the viral proteinase (PR) during virion morphogenesis. Besides cleaving viral polyproteins, which is essential for infectivity, PR of human immunodeficiency virus (HIV) also cleaves cellular proteins and PR expression causes a pronounced cytotoxic effect. Retroviral PRs are aspartic proteases and contain two copies of the triplet Asp-Thr-Gly in the active center with the threonine adjacent to the catalytic aspartic acid presumed to have an important structural role. We have changed this threonine in HIV type 1 PR to a serine. The purified mutant enzyme had an approximately 5- to 10-fold lower activity against HIV type 1 polyprotein and peptide substrates compared with the wild-type enzyme. It did not induce toxicity on bacterial expression and yielded significantly reduced cleavage of cytoskeletal proteins in vitro. Cleavage of vimentin in mutant-infected T-cell lines was also markedly reduced. Mutant virus did, however, elicit productive infection of several T-cell lines and of primary human lymphocytes with no significant difference in polyprotein cleavage and with similar infection kinetics and titer compared with wild-type virus. The discrepancy between reduced processing in vitro and normal virion maturation can be explained by the observation that reduced activity was due to an increase in Km which may not be relevant at the high substrate concentration in the virus particle. This mutation enables us therefore to dissociate the essential function of PR in viral maturation from its cytotoxic effect.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7474139      PMCID: PMC189639     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Proteolytic cleavage of microtubule-associated proteins by retroviral proteinases.

Authors:  M Wallin; J Deinum; L Goobar; U H Danielson
Journal:  J Gen Virol       Date:  1990-09       Impact factor: 3.891

2.  Use of T7 RNA polymerase to direct expression of cloned genes.

Authors:  F W Studier; A H Rosenberg; J J Dunn; J W Dubendorff
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

3.  Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease.

Authors:  A Wlodawer; M Miller; M Jaskólski; B K Sathyanarayana; E Baldwin; I T Weber; L M Selk; L Clawson; J Schneider; S B Kent
Journal:  Science       Date:  1989-08-11       Impact factor: 47.728

4.  Standardized and simplified nomenclature for proteins common to all retroviruses.

Authors:  J Leis; D Baltimore; J M Bishop; J Coffin; E Fleissner; S P Goff; S Oroszlan; H Robinson; A M Skalka; H M Temin
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

5.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

6.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein.

Authors:  R L Shoeman; B Höner; T J Stoller; C Kesselmeier; M C Miedel; P Traub; M C Graves
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

8.  Expression in Escherichia coli and purification of human immunodeficiency virus type 1 capsid protein (p24).

Authors:  L S Ehrlich; H G Krausslich; E Wimmer; C A Carter
Journal:  AIDS Res Hum Retroviruses       Date:  1990-10       Impact factor: 2.205

9.  Specificity studies on retroviral proteinase from myeloblastosis-associated virus.

Authors:  P Strop; J Konvalinka; D Stys; L Pavlickova; I Blaha; J Velek; M Travnicek; V Kostka; J Sedlacek
Journal:  Biochemistry       Date:  1991-04-09       Impact factor: 3.162

10.  Restricted expression of human T-cell leukemia--lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes.

Authors:  S Z Salahuddin; P D Markham; F Wong-Staal; G Franchini; V S Kalyanaraman; R C Gallo
Journal:  Virology       Date:  1983-08       Impact factor: 3.616

View more
  48 in total

1.  Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway.

Authors:  P O Falnes; R Welker; H G Kräusslich; S Olsnes
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

2.  Viral evolution in response to the broad-based retroviral protease inhibitor TL-3.

Authors:  B Bühler; Y C Lin; G Morris; A J Olson; C H Wong; D D Richman; J H Elder; B E Torbett
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus.

Authors:  B Etemad-Moghadam; D Rhone; T Steenbeke; Y Sun; J Manola; R Gelman; J W Fanton; P Racz; K Tenner-Racz; M K Axthelm; N L Letvin; J Sodroski
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative.

Authors:  Barbara Müller; Jessica Daecke; Oliver T Fackler; Matthias T Dittmar; Hanswalter Zentgraf; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

5.  HIV-1 protease has a genetic T-cell adjuvant effect which is negatively regulated by proteolytic activity.

Authors:  Kwang Soon Kim; Dong Bin Jin; So Shin Ahn; Ki Seok Park; Sang Hwan Seo; You Suk Suh; Young Chul Sung
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

6.  The cellular protein lyric interacts with HIV-1 Gag.

Authors:  Christine E Engeland; Heike Oberwinkler; Michael Schümann; Eberhard Krause; Gerd A Müller; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

7.  Analysis of human immunodeficiency virus type 1 Gag ubiquitination.

Authors:  Eva Gottwein; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein.

Authors:  J Konvalinka; M Löchelt; H Zentgraf; R M Flügel; H G Kräusslich
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir.

Authors:  Klára Grantz Sasková; Milan Kozísek; Martin Lepsík; Jirí Brynda; Pavlína Rezácová; Jana Václavíková; Ron M Kagan; Ladislav Machala; Jan Konvalinka
Journal:  Protein Sci       Date:  2008-06-17       Impact factor: 6.725

10.  Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef.

Authors:  Roger G Ptak; Brian G Gentry; Tracy L Hartman; Karen M Watson; M Clayton Osterling; Robert W Buckheit; Leroy B Townsend; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.